T H E A S P E N R E T I N A L D E T A C H M E N T S O C I E T Y

“Oh vitreous where is thy humor”

ACCREDITATION AND CREDIT DESIGNATION

This activity has been planned and implemented in accordance with the accreditation requirements and

policies of the Accreditation Council for Continuing Medical Education through the joint providership of

William Beaumont Hospital, Medical Conference Planners, Inc. and the Aspen Retinal Detachment Society.

William Beaumont Hospital is accredited by the ACCME to provide continuing medical education for physicians.

William Beaumont Hospital designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credit(s).™

Physicians should claim only the credit commensurate with the

extent of their participation in the activity.

MARCH 5–9, 2016 • SNOWMASS, COLORADO

ARDS 2016 • SNOWMASS, COLORADO 3

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Activity Directors

Donald J. D’Amico, MDWeill Cornell Medical CollegeNew York-Presbyterian HospitalNew York, NY

Timothy G. Murray, MD, MBAMurray Ocular Oncology and RetinaMiami, FL

Guest Faculty

Neil M. Bressler, MDJohns Hopkins Wilmer Eye InstituteBaltimore, MDTAYLOR SMITH LECTURE

R.V. Paul Chan, MDIllinois Eye and Ear InfirmaryChicago, IL

Harry W. Flynn, Jr., MDBascom Palmer Eye InstituteMiami, FL

Tarek S. Hassan, MDAssociated Retinal ConsultantsRoyal Oak, MI

Glenn J. Jaffe, MDDuke Eye CenterDurham, NC

Founders

William O. Edward, MD1930–2012

Ottiwell W. Jones, III, MDSpokane, WA

Mark W. Johnson, MDKellogg Eye CenterAnn Arbor, MIFOUNDERS LECTURE

Szilárd Kiss, MDWeill Cornell Medical CollegeNew York-Presbyterian HospitalNew York, NY

David W. Parke, II, MDAmerican Academy of OphthalmologySan Francisco, CA

Giovanni Staurenghi, MDUniversity of MilanMilan, Italy

Meeting Planner

Karen BaranickMedical Conference Planners, Inc.Scarsdale, NY

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Mark W. Johnson, MD, is Professor of

Ophthalmology and Visual Sciences and

Director of the Retina Service at the

University of Michigan in Ann Arbor. An

honors graduate of the University of Utah

School of Medicine, Dr. Johnson completed

residency training at the University of

Michigan Kellogg Eye Center, where he served as

Chief Resident. He completed a year of medical

retina fellowship with Dr. Donald Gass at the

Bascom Palmer Eye Institute, followed by a year of

fellowship training in vitreoretinal surgey at the

same institution.

Dr. Johnson is a fellow of the American Academy

of Ophthalmology and received its Honor Award

in 1997 and its Senior Achievement Award in

2005. He was elected to active membership in the

American Ophthalmological Society in 2005, and

is recognized in Best Doctors in America and Guide to

America’s Top Physicians. He has served as Associate

Examiner for the American Board of Ophthalmology

since 1995. He serves on the editorial boards of

the American Journal of Ophthalmology, Retina,

and Retinal Physician.

Dr. Johnson has served on the Board of Directors

of the American Society of Retina Specialists

and as chairperson for committees of the Macula

and Retina Societies. He was elected

President of The Retina Society in 2015.

He has served as a member of the

Update/Special Focus Course Committee

and the Basic and Clinical Science

Course Committee of the American

Academy of Ophthalmology, the

Committee on Programs of the American

Ophthalmological Society, and the Periodic

Ophthalmic Review Tests (PORT) Panel of the

American Board of Ophthalmology.

Dr. Johnson’s chief clinical research interests

include pharmacotherapies for macular diseases

and pathogenesis and treatment of vitreomacular

interface disorders. He has served as principal

investigator and Data and Safety Monitoring

Committee member for numerous national multi-

center clinical trials in age-related macular

degeneration, retinal vascular disease, and vitreo-

retinal disorders. He lectures widely on topics in

macular and vitreoretinal disease and has published

over 175 articles and book chapters.

Founders Honorees

2012 Steve Charles, MD

2013 Joan W. Miller, MD

2014 Carl D. Regillo, MD

2015 Dean Eliott, MD

4 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

FOUNDERS LECTURE

MONDAY, MARCH 7, 2016 • 6:55 PM

Ocriplasmin Retinopathy: Characteristics, Mechanism, Incidence,

and ReversibilityMARK W. JOHNSON, MD

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ARDS 2016 • SNOWMASS, COLORADO 5

Neil M. Bressler, MD, graduated from

the Johns Hopkins University School

of Medicine in 1982 and completed an

ophthalmology residency at Harvard

Medical School’s Massachusetts Eye

and Ear Infirmary in 1986. He joined

the Wilmer Eye Institute (Department of

Ophthalmology) faculty at Johns Hopkins in

1988, where he currently is Chief of the

Retina Division with 19 full-time clinical

faculty in retina and has an endowed chair as

the inaugural James P. Gills Professor of

Ophthalmology.

Dr. Bressler has authored

approximately 350 peer-reviewed

publications, continues to work on

the NIH-sponsored Diabetic

Retinopathy Clinical Research

Network that he chaired for seven

years and currently chairs the National Eye

Institute’s Data and Safety Monitoring

Committee for intramural clinical trials. He

also has been Chair of the FDA Ophthalmic

Devices Panel and has been Editor-in-Chief of

JAMA Ophthalmology and on The JAMA

Network Editorial Board of JAMA since 2013.

Taylor Smith Honorees

1983 Thomas M. Aaberg, Sr., MD

1984 Robert E. Morris, MD

1985 Michael Shea, MD

1986 Alexander Ray Irvine, Jr., MD

1987 William H. Spencer, MD

1988 Victor T. Curtin, MD

1989 Alan Bird, MD

1990 J. Donald M. Gass, MD

1991 Robert J. Brockhurst, MD

1992 Stephen J. Ryan, MD

1993 Wayne E. Fung, MD

1994 Charles P. Wilkinson, MD

1995 George W. Blankenship, MD

1996 Mary Lou Lewis, MD

1997 Donald J. D’Amico, MD

1998 Stanley Chang, MD

1999 Harry W. Flynn, Jr., MD

2000 Ian J. Constable, MD

2001 Thomas R. Friberg, MD

2002 William S. Tasman, MD

2003 Evangelos S. Gragoudas, MD

2004 Steve Charles, MD

2005 Thaddeus P. Dryja, MD

2006 Jerry A. Shields, MD

2007 Mark S. Blumenkranz, MD

2008 Allan E. Kreiger, MD

2009 Alexander R. Gaudio, MD

2010 Carmen A. Puliafito, MD, MBA

2011 David W. Parke, II, MD

2012 J. Brooks Crawford, MD

2013 Michael T. Trese, MD

2014 Julia A. Haller, MD

2015 George A. Williams, MD

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

TAYLOR SMITH LECTURE

TUESDAY, MARCH 8, 2016 • 6:50 PM

Impact of Recent DRCR.net Randomized Clinical Trial Results on Managing Diabetic Retinopathy in 2016

NEIL M. BRESSLER, MD

PROGRAM AT A GLANCE

SaturdayM A R C H 5

4:00–9:00 PM

RegistrationViceroy Snowmass(Spa Level – Salon 2)

6:00–9:00 PM

Welcome Dinner Viceroy Snowmass(Spa Level – Salon 2)

SundayM A R C H 6

3:30–4:00 PM

Break

3:30–7:30 PM

Exhibits

4:00–4:20 PM

Recurrent Macular Holes in the Era of Small-GaugeVitrectomy Tarek S. Hassan, MD

4:20–4:35 PM

Discussion

4:35–4:55 PM

Intravitreal Pharmacotherapy in Complex Ocular Disease:Where Are We in 2016?Timothy G. Murray, MD, MBA

4:55–5:10 PM

Discussion

5:10–5:30 PM

OCT Angiography Giovanni Staurenghi, MD

5:30–5:45 PM

Discussion

5:45–6:15 PM

Break

6:15–6:35 PM

Imaging in Posterior Uveitis Glenn J. Jaffe, MD

6:35–6:50 PM

Discussion

6:50–7:30 PM

PANEL 1:

Age-related MacularDegeneration Moderator: Szilárd Kiss, MD Panelists: Neil M. Bressler, MD, R.V. Paul Chan, MD, Glenn J. Jaffe, MD,Giovanni Staurenghi, MD

7:30 PM

Adjourn/Free Evening

MondayM A R C H 7

3:30–4:00 PM

Break

3:30–7:30 PM

Exhibits

4:00–4:20 PM

New Treatments forIntermediate, Posterior, and Panuveitis Glenn J. Jaffe, MD

4:20–4:35 PM

Discussion

4:35–4:55 PM

Promising New Treatments forRetinal Diseases: Gene Therapyand Engineered Cells Szilárd Kiss, MD

4:55–5:10 PM

Discussion

5:10–5:30 PM

Management Options for VMT:What’s New in 2016 Harry W. Flynn, Jr., MD

5:30–5:45 PM

Discussion

5:45–6:15 PM

Break

6:15–6:55 PM

PANEL 2:

Vitreoretinal Surgery Moderator: R.V. Paul Chan, MD Panelists: Donald J. D’Amico, MD, Harry W. Flynn, Jr., MD, Tarek S.Hassan, MD, Mark W. Johnson, MD

6:55–7:00 PM

Introduction of Mark W. Johnson, MD Timothy G. Murray, MD, MBA

7:00–7:20 PM

FOUNDERS LECTURE

Ocriplasmin Retinopathy:Characteristics, Mechanism,Incidence, and Reversibility Mark W. Johnson, MD

7:20–7:30 PM

Discussion

8:00–10:00 PM

Faculty Dinner

6 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

ARDS2016

TuesdayM A R C H 8

11:00 AM–1:30 PM

NASTAR Ski Race and Lunch

3:30–4:00 PM

Break

3:30–7:30 PM

Exhibits

4:00–4:20 PM

Different Preferences between US and EuropeanVitreoretinal SurgeonsDonald J. D’Amico, MD

4:20–4:35 PM

Discussion

4:35–4:55 PM

Changing the Rules in theManagement of Pediatric Retina Disease R.V. Paul Chan, MD

4:55–5:10 PM

Discussion

5:10–5:30 PM

Macular Atrophy in Anti-VEGF Treatment Giovanni Staurenghi, MD

5:30–5:45 PM

Discussion

5:45–6:15 PM

Break

6:15–6:35 PM

Healthcare Policy and Payment in 2020 David W. Parke, II, MD

6:35–6:50 PM

Discussion

6:50–6:55 PM

Introduction of Neil M. Bressler, MD Donald J. D’Amico, MD

6:55–7:20 PM

TAYLOR SMITH LECTURE

Impact of Recent DRCR.netRandomized Clinical TrialResults on Managing DiabeticRetinopathy in 2016 Neil M. Bressler, MD

7:20 –7:30 PM

Discussion

7:30 PM

Adjourn

8:00–10:00 PM

Closing DinnerViceroy Snowmass

WednesdayM A R C H 9

3:30–4:00 PM

Break

3:30–7:30 PM

Exhibits

4:00–4:20 PM

Endophthalmitis: Real World Cases for theVitreoretinal Surgeon Harry W. Flynn, Jr., MD

4:20–4:35 PM

Discussion

4:35–4:55 PM

A Controlled Comparison of the Dexamethasone Implant vs.Intravitreal anti-VEGF Therapyfor Diabetic Macular Edema Tarek S. Hassan, MD

4:55–5:10 PM

Discussion

5:10–5:30 PM

Myopic Traction Maculopathy:Mechanisms and Treatment Mark W. Johnson, MD

5:30–5:45 PM

Discussion

5:45–6:15 PM

Break

6:15–6:35 PM

Novel Management of Enhanced S-cone Syndrome Donald J. D’Amico, MD

6:35–6:50 PM

Discussion

6:50–7:30 PM

PANEL 3:

Practice Management 2016 Moderator: Timothy G. Murray, MD, MBAPanelists: R.V. Paul Chan, MD, Donald J. D’Amico, MD, Tarek S.Hassan, MD, Szilárd Kiss, MD

7:30 PM

Adjourn

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . ARDS 2016 • SNOWMASS, COLORADO 7

PROGRAM SUMMARIES

Sunday | MARCH 64:00–4:20 PM

Management of Recurrent Macular Holes in the Era of Small-Gauge Vitrectomy TAREK S. HASSAN, MD

Macular hole repair rates have improved significantlysince 1991 but have leveled off in the past decade,commensurate with the widespread adoption of small-gauge vitrectomy. More experience, better ILM peelingtechnique, improved OCT technology, and bettersurgical visualization have all contributed to theseimprovements.

Macular hole closure occurs with vitrectomy, posteriorhyaloidal removal, and ± ILM removal because tractionis relieved from the hole and a bridge of glial tissue closesthe full thickness defect. Reopening of initially closedmacular holes has been reported to occur in approxi-mately 5-9% of eyes but most series assessing this weredone in the 20g vitrectomy era.

We performed the first extensive look at recurrentmacular holes in eyes treated entirely with 23 or 25gvitrectomy techniques in a retrospective review of nearly400 eyes. We found 13 eyes with reopened macular holes(3.3%), occurring at a mean of 28 months following theinitial repair. All eyes underwent reoperation and allmacular holes closed again. Three of these 13 eyesreopened for a second time, and two of the patientsdecided not to pursue further surgery. The third macularhole closed with another vitrectomy procedure.

We note the low incidence of macular hole failure anddescribe the potential anatomic findings that mayexplain reasons for the hole reopenings. We also notecorrelations between the other eyes of such patients withrecurrent macular holes and the published literature.

4:35–4:55 PM

Intravitreal Pharmacotherapy in Complex Ocular Disease: Where Are We in 2016?TIMOTHY G. MURRAY, MD, MBA

The last 5 years have seen marked advances in vitreo-retinal surgical management. Enhanced, integratedsurgical platforms now incorporate high speed cutting,fluidic stabili zation, and widefield imaging. Significantshifts include valved trocar entry systems, improvedsingle-use instrumentation, and intraoperative pharma-cotherapeutic agents to stabilize retina, image tissuestructures, and modulate surgical morbidities. Thispresentation will use case based video analysis tohighlight the indications, applications and expectedoutcomes for the use of advanced intravitreal pharma-cotherapy as it relates to vitrectomy surgery. Clinicalpearls will be discussed including approaches to minimizeintraoperative and postoperative complicationsassociated with the use of these novel agents.

5:10–5:30 PM

OCT Angiography GIOVANNI STAURENGHI, MD

Optical coherence tomography angiography (OCT-A)has evolved significantly over the past few years. Unliketraditional angiography, it does not require an injectionfor the patient because the OCT relies on the motion ofblood cells through the blood vessels as contrast.

There are on the market already two devices and otherswill come in the near future. Different companies usedifferent algorithms. Some use variance of amplitude,full or split spectrum, other the combination of changesin phase and amplitude.

There are a series of considerations that we should keepin mind when we interpret an OCT-A image.

• To summarize the images of an OCT-A are the repre-sentation of moving particles in the eye vessels but donot always correspond to the anatomy of the vessels.

• The location of the slab for the best vascular lesionsvisualization do not always correspond to the rightanatomical location

8 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

• Most of the time it is impossible to differentiatearteries and veins

• Due to speed limitations some vessels or vesseldilatation such as microaneurisms are not alwaysvisualized

• The projection artifacts should be considered for thebest interpretation of the images

• The lack of leakage detection

• The advantage of high contrast allowed a better identi-fication of not perfused retinal areas and choroidal newvessels

• For the choroid can substitute a static indocyaninegreen angiography (ICGA)

• It is the best imaging tool to visualize choriocapillary

The evolution of technologies and the improvement ofinterpretation of the images will give us another imagingtool to add to our armamentarium to help in a betterdifferential diagnosis of eye diseases.

6:15–6:35 PM

Imaging in Posterior Uveitis GLENN J. JAFFE, MD

An increasing number of imaging modalities areavailable to evaluate and manage patients with uveitis.Uveitis is a group of diseases with varied presentations.Accordingly, it is appropriate to tailor the imagingmethods, often with a multimodal approach, based onthe specific type of uveitis, or group of conditions thatare considered in the differential diagnosis, to extract the maximum diagnostic information, and to minimizeunnecessary testing. Each of the imaging techniques hasstrengths and weaknesses, and are often complementary.They may be useful not only to establish a diagnosis andto monitor treatment benefit, but to assess the efficacy of a therapeutic intervention in a clinical trial.

Specific imaging methods include fluorescein angiography(FA), indocyanine green angiography (ICGA), colorfundus photography (CFP), ultrasonography, fundusautofluorescence, optical coherence tomography (OCT),and OCT-angiography (OCTA). Fluorescein angiog-raphy is used to assess CME, white dot syndromes, VKH,

sympathetic ophthalmia, and posterior scleritis, placoidsyphilitic uveitis, AMPPE and serpiginous choroiditis,and retinitis. ICGA is appropriate to assess white dotsyndromes, sarcoid, AMPPE and serpiginous choroiditis,and VKH. CFP, particularly ultrawidefield CFP is usefulto monitor change in chorioretinal lesions in a variety of conditions.

Ultrasound is helpful when media opacity precludesimaging by other methods, and is especially helpful forpre-surgical planning. OCT is useful to assess retinal and choroidal thickness, morphological characteristicsincluding vitreoretinal interface changes, retinalmicrostructure, intraretinal, subretinal, and choroidalfluid, and hyper-reflective dots, and A/C cells. OCTAcan be used to determine vascular flow, and location of abnormal vessels. As imaging methods evolve, they will play an even greater role in the management of uveitis.

6:50–7:30 PM

PANEL 1: Age-related Macular Degeneration MODERATOR: SZILÁRD KISS, MD

Panelists: Neil M. Bressler, MD, R.V. Paul Chan, MD,Glenn J. Jaffe, MD, Giovanni Staurenghi, MD

The last decade has been marked by a revolution in the diagnosis, treatment and prognosis for our patientswith wet age-related macular degeneration. The anti-vascular endothelial growth factor revolution – usheredin 10 years ago with the FDA approval of ranibizumab –has been paralleled by a revolution in retinal imaging,especially with the ever-growing reliance on opticcoherence tomography to guide our treatment. The panelof esteemed experts will discuss their current approach to diagnosing, treating and following patients withneovascular AMD. They will also provide insight as to what lies on the horizon – including the potentialclinical utility of OCT angiography, combination therapy,sustained delivery strategies, and potential treatments for dry age-related macular degeneration.

ARDS 2016 • SNOWMASS, COLORADO 9

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Monday | MARCH 74:00–4:20 PM

New Treatments for Intermediate,Posterior, and Panuveitis GLENN J. JAFFE, MD

There are a variety of options available to treat patientswith intermediate, posterior, and panuveitis, and neweroptions that will likely become available within the next1-2 years. Corticosteroids, given topically, as a periocular,or intravitreal injection, as an intravitreal sustained drugdelivery implant (dexamethasone (DDS) and fluocinoloneacetonide (FA) delivery systems), or systemically havebeen the primary therapy for intermediate, posterior, orpanuveitis. These agents are very effective, but all maycause cataract and elevated intraocular pressure, andsystemic treatment has a myriad of side effects that areoften treatment-limiting.

Currently available shorter-term delivery methods,include intravitreal triamcinolone acetonide (TA)injection, periocular steroid injection, and DDS.However, these methods may not produce a drug effectsufficiently long, without relatively frequent re-injection,to manage these chronic inflammatory diseases. Long-term delivery systems such as the FA implant aretypically effective for 3 years or more, but must be surgically implanted.

Recently, we have investigated an injectable FA implantthat can be placed in the office, and that releases drugfor 2-3 years. In an individual investigator-sponsoredtrial, this agent very effectively controlled inflammationfor at least 2 years, improved visual acuity, reducedancillary-anti-inflammatory drug use, and had a favorablesafety profile. Furthermore, a phase 3 study of thisdelivery system met its primary 6-month therapeuticendpoint.

There have been few successful clinical trials of non-steroidal systemic anti-inflammatory therapy. Recently,two pivotal phase 3 studies of adalimumab for active and inactive uveitis, respectively, met the primary, studyendpoint, time to treatment failure, when used assteroid-sparing therapy. This agent could be the firststeroid-sparing immunomodulatory treatment approvedfor non-infectious intermediate, posterior, or panuveitis.

4:35–4:55 PM

Promising New Treatments forRetinal Diseases: Gene Therapy and Engineered Cells SZILÁRD KISS, MD

The eye – as a self-contained, comparatively small, andrelatively immune privileged organ – offers a perfect sitefor applying gene and cellular therapy techniques for the treatment of a wide range of acquired and inheriteddisorders. Decades of preclinical proof-of-conceptlaboratory effort have resulted in several promising andexciting clinical applications.

Gene therapy – where a non-pathologic viral vector isengineered to delivery a protein of choice – is beingapplied not only to mono genetic inherited disorderswhich currently cannot be otherwise treated (such asLeber’s Congenital Amaurosis and X-linked Retino -schesis) but also to acquired disorders such as maculardegeneration and diabetic retinopathy that requirerepeated intravitreal injections indefinitely. Engineeredcells – where cells are transformed ex vivo to producethe protein of choice (such as Encapsulated CellTechnology) – can be implanted into the eye andremoved if necessary, offering a form of reversible andperhaps a fine tunable gene therapy.

Other types of engineered and transformed cells selectedfor their specificity (such as cytotoxic CMV specific T-cells) can be infused systemically and act in the eye toward off opportunistic infections that are beginning toresurface. Finally, terminally differentiated as well aspluripotent stem cells can be injected into the eye to‘regenerate’ areas of the retina and perhaps restore visualfunction in disorders previous thought to be untreatable(such as reversing geography atrophy from AMD andrestoring vision in Stargdart’s disease).

6:15–6:55 PM

PANEL 2: Vitreoretinal Surgery MODERATOR: R.V. PAUL CHAN, MD

Panelists: Donald J. D’Amico, MD, Harry W. Flynn, Jr., MD,Tarek S. Hassan, MD, Mark W. Johnson, MD

Drs. D’Amico, Flynn, Johnson and Hassan will discusstheir approach to the evaluation and surgical manage -ment of various vitreoretinal conditions includingcomplex diabetic retinopathy, retinal detachment,

10 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

macular pathology, proliferative vitreoretinopathy,uveitis, and pediatric vitreoretinal disease. Thediscussion will be focused on current surgical techniquesand instrumentation.

7:00–7:20 PM

FOUNDERS LECTURE Ocriplasmin Retinopathy:Characteristics, Mechanism,Incidence, and Reversibility MARK W. JOHNSON, MD

Review of safety data from phase 2 and 3 clinical trialscombined with numerous postmarketing reports revealthat ocriplasmin injection may cause substantial acutepanretinal structural and functional abnormalities in asubset of eyes.

The symptoms and signs of acute ocriplasminretinopathy include varying degrees of the following:acute reduction in visual acuity (sometimes to very lowlevels), bizarre photopsias (eg. continuous bright curvedor kaleidoscopic lines, sparkles, white floaters on a darkbackground), dyschromatopsia (eg. chromatic tinting,black and white or “negative” vision), nyctalopia, visualfield constriction, afferent pupillary defect, anisocoria,retinal vascular attenuation or constriction, disruption/loss of outer retinal signals on spectral domain opticalcoherence tomography (SD-OCT) imaging, macularhole enlargement, macular detachment, reduced(sometimes flat) ERG responses, autofluorescence abnormalities, and lens subluxation or phacodonesis.

Enzymatic degradation of laminin and/or otherintraretinal proteins by this nonspecific protease is themechanism that most plausibly explains the variousmanifestations of the retinopathy. Although theincidence of acute retinal dysfunction after ocriplasmininjection is unknown, the best available evidencesuggests that some degree of retinopathy occurs in 30 to 50% of eyes.

Most of the retinal adverse effects have been shown tobe transient or mostly reversible over time, typicallywithin 2-3 months after injection. However, somereports show that visual acuity loss, nyctalopia, ERGchanges, ellipsoid zone alterations and/or subretinal fluidmay persist in some patients beyond 6 months of follow-up. Ocriplasmin should be used with caution pendingfurther study results about the mechanism, incidence,and reversibility of its harmful effects on the eye.

Tuesday | MARCH 84:00–4:20 PM

Different Preferences between US and European Vitreoretinal SurgeonsDONALD J. D’AMICO, MD

Surgical disciplines are enriched by the wide diversity of techniques employed by surgeons in their particularsurgical environments. A surgeon’s preferences for givenmaneuvers and approaches are influenced by manyfactors including personal experience, influence ofmentors, advances in technology and disease under-standing, prevailing preferences of close colleagues in the practice environment, differential reimbursementincentives, instrument costs, personal attitude (con -servative versus eager) toward trying new approaches,and bias, to name but a few.

This presentation offers the author’s personal observa-tions on different preferences in surgical technique andsurgical setting between vitreoretinal specialists in theUnited States and Europe. These impressions, thoughclearly subjective, derive from the author’s extensiveexperience with, and connection to, many vitreoretinalcenters and surgeons around the world in a wide variety of venues.

While the results of surgery and the availability of infor-mation and instrumentation are quite comparable onboth sides, vitreoretinal surgeons in the US are morelikely to 1) use local anesthesia, 2) an outpatient setting,3) perform phakic vitrectomy, 4) use gas as opposed tooil as a tamponade, 5) use pneumatic retinopexy forcertain cases, 6) place an anterior chamber lens forsecondary implantation, and 7) perform intravitrealinjections in the office or exam room. Europeancolleagues more commonly 1) perform combinedphacoemulsification with intraocular lens implantationat the time of vitrectomy, 2) use perfluorochemicalsduring retinal detachment surgery, and 3) utilize heavysilicone oils. These observations suggest that manyfactors, both medical and non-medical, influence vitreo-retinal surgeons and result in differing preferences forsurgical techniques and surgical setting.

ARDS 2016 • SNOWMASS, COLORADO 11

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

4:35–4:55 PM

Changing the Rules in theManagement of Pediatric Retina Disease R.V. PAUL CHAN, MD

The management of pediatric retinal disease has beenevolving rapidly with significant advances in imagingand surgical technology over the past ten years.Although we have historically based our diagnostic and treatment decisions almost exclusively through thefindings seen on examination by indirect ophthal-moscopy, the advent of imaging systems that are able tobetter accommodate children has improved our medicaland surgical management of pediatric retinal conditions.Both non contact ultra-widefield retinal imaging withthe Optos 200Tx or California (OPTOS, Marlborough,MA) and contact imaging systems, such as the RetCam(Clarity Medical Systems, Pleasanton, CA) andPanoCam (Visunex Medical Systems, Fremont, CA),have made it possible to better evaluate peripheralretinal pathology in the pediatric population both in theoutpatient and hospital setting.

With these advances we are now provided with newinformation that will enable us to rethink our previousmanagement algorithms for pediatric retina. We haverecently shown that fluorescein angiography and mosaicimaging may affect how pediatric retina experts diagnoseand manage retinopathy of prematurity (ROP). Imaginghas also influenced our classification of disease, andtherefore potentially providing prognostic markers forfamilial exudative vitreoretinopathy (FEVR) and otherpediatric vitreoretinopathies. Current advances insurgical and medical technology also make it necessaryfor us to reevaluate our surgical decision making forchildren.

The changing trends for managing pediatric retinapatients will be discussed with an emphasis on the role ofultra-widefield imaging, fluorescein angiography, opticalcoherence tomography, computer-facilitated imageanalysis, and MIVS.

5:10–5:30 PM

Macular Atrophy in Anti-VEGF Treatment GIOVANNI STAURENGHI, MD

Anti VEGF is the treatment for many retinal andchoroidal diseases. It is clear that the correct use of these drugs can improve visions in conditions where thestabilization of vision was considered a big success beforethe anti VEGF-era.

Clinical trials demonstrate the efficacy and shows in thetwo/three years that there are not important side effects.One of the most reported is macular atrophy observed in patients with choroidal neovascularization secondaryto age-related macular degeneration.

There are two different theories:• A direct effect of the drug on choroidal vasculature• A normal evolution of age-related macular degeneration

The talk will show the pro and con of the two theories.

6:15–6:35 PM

Healthcare Policy and Payment in 2020 DAVID W. PARKE, II, MD

Payment follows policy. And policy follows politics.Politics pertaining to healthcare policy have been driven‘top-down’. And they have been primarily driven by twin goals of increasing access to care (increasing thepercentage of Americans with at least catastrophichealth care coverage) and decreasing the aggregate costof care.

12 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

In order to achieve these seemingly contradictory goals,the optics have led to the following assertions andassumptions:• Coordinated care will lead to less expensive,duplicative, and unnecessary care and will save moneythat can be spent on increasing access.

• Coordinated care means primary care-led care systems

• Care systems need to be integrated horizontally andvertically into large systems

• Payment for care needs to be made with providers at risk

• Payment for care should be bundled to disease orepisode of care

• Payment for care should be based primarily on the time needed to render that care

The policies that followed on these assumptions include such acronyms as:• Value-based care• Value-based modifiers• Patient-Centered Medical Homes (PCMH)• Accountable Care Organizations (ACO)• Merit-based Incentive Payment Systems (MIPS)• Alternative Payment Models (APM’s)

As a generality, ophthalmologists are in a uniqueposition in the physician world. The eye care pyramiddepends less on primary care physicians than most otherspecialties. We are not attractive to integrated systems.(We don’t fill hospital beds, use expensive imagingsystems, or use ICU’s.) We do high-volume, low cost perepisode of care work. We are an island. Yet we will besubject to the same regulations as primary care or ashospital-intensive proceduralists. For most, this meanssurviving (and thriving) in the MIPS world.

6:55–7:20 PM

TAYLOR SMITH LECTUREImpact of Recent DRCR.netRandomized Clinical Trial Results on Managing Diabetic Retinopathy in 2016 NEIL M. BRESSLER, MD

Several recent publications by the NIH-sponsoredDiabetic Retinopathy Clinical Research Network havehad a profound impact on considerations in themanagement of diabetic retinopathy. A comparativeeffectiveness trial (Protocol T) evaluated aflibercept,bevacizumab, and ranibizumab for diabetic macularedema (DME) within a randomized clinical trial.

The results showed that, on average, all 3 agents causedimprovement of visual acuity, although there was asignificant interaction of the initial visual acuity on theoutcomes. When visual acuity (Snellen equivalent) was20/50 or worse, aflibercept, on average, was superior toranibizumab or bevacizumab, with no increased safetyconcerns. When visual acuity was 20/32 to 20/40, nosubstantial difference in average visual acuity outcomeswas identified. Another trial (Protocol S) comparedranibizumab to panretinal photocoagulation (PRP) forproliferative diabetic retinopathy. Anti-vascularendothelial growth factor (anti-VEGF) visual acuityoutcomes were no worse than (non-inferior to) PRP butresulted in substantially less average visual field loss, farfewer vitrectomies, and less likelihood of developingDME for which anti-VEGF treatment would be indicatedamong eyes without such DME at the time of initiatingtreatment for PDR.

Treatments typically involved 6 monthly treatments withone exception (no DME and visual acuity 20/20 forDME cases, or no PDR for PDR cases) and then noadditional treatment if the DME or PDR no longer wasimproving, but resumption of anti-VEGF treatment ifDME or PDR worsened after it was withheld. Visitsdoubled to 2 and then 4 months starting in the secondyear after initiating therapy if DME or PDR remainedstable in the absence of anti-VEGF treatment.

ARDS 2016 • SNOWMASS, COLORADO 13

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Wednesday | MARCH 94:00–4:20 PM

Endophthalmitis: Real World Casesfor the Vitreoretinal Surgeon HARRY W. FLYNN, JR., MD

Vitreoretinal surgeons usually manage patients withendophthalmitis. Injecting intravitreal antibiotics andusing vitrectomy in selected cases are part of routine careby retinal specialists. Treatment now is performed on anoutpatient basis and systemic antibiotics are optional butcan be considered in more advanced cases.

The Endophthalmitis Vitrectomy Study (EVS) was a land -mark study (1991-1994) showing better visual outcomesusing PPV (compared to tap and inject)in patients withlight perception visual acuity from endophthalmitis aftercataract surgery. Newer studies have validated the EVSin terms of the effectiveness of pars plana vitrectomy for eyes with more advanced visual loss. Even thoughpresenting visual acuity is better than light perception,many vitreoretinal surgeons appropriately consider the use of vitrectomy in eyes with more advancedinflammation or in eyes with more virulent organismsdemonstrated on the initial tap and inject procedure.

Based on the specific etiology of the infection, thecausative organism can often be predicted: 1. Acute-onset postoperative endophthalmitis following

cataract surgery: Coag neg Staph.2. Delayed-onset pseudophakic endophthalmitis:

P. acnes. 3. Delayed-onset, conjunctival filtering bleb associated

endophthalmitis: streptococcus species.4. Post-traumatic endophthalmitis: bacillus species 5. Endogenous endophthalmitis: candida species6. Intravitreal injection related endophthalmitis:

staphylococcus and streptococcus species.

The use of silicone oil can be considered in moreadvanced endophthalmitis cases. Although there arelimited studies on the use of silicone oil, oil may reducerates of postvitrectomy retinal detachment or phthisisbulbi. Because of the high rate of complex retinal detach -ment with PVR in eyes with open globe injuries, siliconeoil can be often considered in this setting. Silicone oildoes not support the growth or microbes and thereforewill reduce ongoing proliferation of microbes during thepostoperative course. Antibiotics can be used intraopera-tively and postoperatively in these silicone oil cases.

4:35–4:55 PM

A Controlled Comparison of theIntravitreal Dexamethasone Implantvs. Intravitreal anti-VEGF Injectionsfor Diabetic Macular EdemaTAREK S. HASSAN, MD

Treatment of chronic DME with anti-VEGF injectionsmay require a lengthy course and ultimately producesuboptimal results. It has become increasingly acceptedthat there are two pathophysiologic pathways thatcontribute to DME formation, the VEGF-mediatedpathway (treated with anti-VEGF medication) and theinflammatory pathway (treated with corticosteroids), andeach may be approached independent of one another.

We report a prospective trial that compared a series ofthree monthly intravitreal ranibizumab injections to the single intravitreal injection of the dexamethasoneimplant, performed by random assignment in matchedeyes of the same patients, to assess the short term differ-ences between the two treatments.

Eleven patients (22 eyes) were assessed. All had matchedeyes with respect to VA, central macular thickness, andamount and type of prior intravitreal anti-VEGF treatment.Patients had stable, well-controlled blood sugars. Oneeye of each patient continued ranibizumab monthly X 3 and the other received the one time injection of thedexamethasone implant without additional ranibizumab.

At month 4, we found equal VAs and degreee ofimprovement between each group but the eyes receivingthe dexamethasone implant had significantly greaterreduction in central macular thickness. Patients weregiven a choice as to their continued treatment and 8 of the 11 patients chose to continue to have thedexamethasone implant placed in both eyes.

We demonstrated that in matched eyes, there was agreater reduction in DME in those that had their treat mentchanged to the dexamethasone implant than in those thatcontinued with their monthly ranibizumab therapy.

5:10–5:30 PM

Myopic Traction Maculopathy:Mechanisms and Treatment MARK W. JOHNSON, MD

Myopic traction maculopathy (MTM) is an extensiveschisis-like thickening in the outer retina of highlymyopic eyes with posterior staphyloma. In addition to

14 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

the outer schisis-like thickening, there may be otherfindings, including inner retinal fluid, foveal detachment,and lamellar or full-thickness macular hole. This disorderoccurs in a substantial portion of patients with patho-logic myopia. The pathoanatomical features have beencharacterized since the advent of optical coherencetomography (OCT) and intuitively suggest a gradualstretching or splitting of the retina over time, likelycaused by relative tautness of the inner retina comparedwith the outer retina within the concavity of theposterior staphyloma.

The precise cause of traction is still debated. Someauthors argue for a preretinal structure, such as aremnant cortical vitreous layer after PVD or obviousepiretinal membrane (ERM). Others have argued thatMTM is caused by something intrinsic to the retina, suchas the internal limiting membrane (ILM) or the stiffnessof retinal arterioles. There is good evidence that thecause of the inner retinal noncompliance in MTM is not uniform but varies from one eye to another. At leastfour major traction mechanisms have been identified:• Vitreomacular traction (associated with perifoveal PVD)

• Remnant cortical vitreous layer (vitreoschisis during PVD)

• Epiretinal membrane• Intrinsic noncompliance of the ILM

Although successful surgical repair can be tailored to thespecific pathologic mechanism(s) operating in a giveneye, wide ILM peeling, possibly with a foveal sparingtechnique in selected eyes, is the surest way to resolve all possible traction mechanisms. Anatomic and visualresults are generally favorable.

6:15–6:35 PM

Novel Management of Enhanced S-cone Syndrome DONALD J. D’AMICO, MD

Enhanced S-Cone Syndrome is an extremely rareautosomal recessive retinal degeneration with nightblindness and variably progressive visual loss that wasfirst identified in 1990. It is caused by a mutation in therod-specific NR2E3 transcription factor leading to anoverpopulation of the retina with S cones. Patientsdisplay a nummular pattern of retinal pigmentation

which may be confused with retinitis pigmentosa, andalso may present with a striking macular schisis. Thediagnosis is confirmed by both genetic and ERG testingwith the latter displaying enhanced short-wavelengthsensitivity, absent rod function, and a delayed, low-amplitude 30-Hz flicker.

This presentation describes the author’s experience withan affected patient who suffered visual loss in associationwith progressive macular schisis, and the author’sattempts to medically (acetazolamide systemically andtopically) and surgically (vitrectomy, ILM peeling, gasinjection) arrest the schisis progression. Initial treatmentwith systemic acetazolamide was unsuccessful, andsurgery itself was unsuccessful; however, the patientsubsequently became responsive to acetazolamide system-ically and topically at very low doses, and has maintainedvisual acuity stability with schisis collapse for severalyears. This patient represents the first known ILMpeeling for macular schisis in this condition, andhighlights the complexity of addressing the structuralretinal abnormalities in association with Enhanced S-Cone Syndrome.

6:50–7:30 PM

PANEL 3: Practice Management 2016 MODERATOR: TIMOTHY G. MURRAY, MD, MBA

Panelists: R.V. Paul Chan, MD, Donald J. D’Amico, MD,Tarek S. Hassan, MD, Szilárd Kiss, MD

Healthcare policy is undergoing rapid transformationthat is directly impacting the clinical practice of thevitreoretinal specialist. This panel will discuss majorshifts in coding (ICD 10), documentation (EHRfocused), and compliance. Specific focus on evolvingshort-term strategies to enhance the practice environ -ment will be targeted. This panel will incorporatespecialists both in Academic and Private based clinicalpractice to more broadly address these critical issueswithin the context of real-world ophthalmology.

ARDS 2016 • SNOWMASS, COLORADO 15

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Bryan Angle, MD Guest: Suzen San Angelo, TX USA(325) 245-7333obtuse443@yahoo.comFellowship: South Texas Retina# of prior years at ARDS: 0

Robert L. Avery, MD Santa Barbara, CA USA(805) 963-1648avery1@jhu.eduFellowship: Duke University# of prior years at ARDS: 20

Carl C. Awh, MD Guests: Grace, Robert, Caroline Nashville, TN USA(615) 479-1052carlawh@gmail.comFellowship: Duke University# of prior years at ARDS: 9

William L. Benedict, MD Guest: Robert Longmont, CO USA(303) 682-3383bbretina@gmail.comFellowship: Texas Tech University# of prior years at ARDS: 15

James Borthwick, FRANZCO Guest: Stephen Christ Church, New Zealand+64-21888481jborthwick@xtra.co.nzFellowship: Sydney Eye Hospital# of prior years at ARDS: 22

Neil M. Bressler, MD (Faculty)Baltimore, MD USA(410) 370-3703nmboffice@jhmi.eduFellowship: Wilmer Eye Institute# of prior years at ARDS: 2

Guri Bronner, MD Gladwyne, PA USA(610) 525-5354guribron@yahoo.comFellowship: Vanderbilt Eye Institute# of prior years at ARDS: 8

Petros E. Carvounis, MD Houston, TX USA(703) 582-1749carvounis@yahoo.comFellowship: Baylor College of Medicine# of prior years at ARDS: 4

Alessandro A. Castellarin, MD Guests: Francesca, Luca and Stephanie Liu Santa Barbara, CA USA(661) 904-4019aacastellarin@yahoo.comFellowship: Emory University# of prior years at ARDS: 9

R.V. Paul Chan, MD (Faculty)Chicago, IL USA(215) 327-4693rvpchan@gmail.comFellowship: Massachusetts Eye and Ear Infirmary# of prior years at ARDS: 10

Sai Chavala, MD Fort Worth, TX USA(216) 849-0437sai.chavala@unthsc.eduFellowship: Duke University# of prior years at ARDS: 1

Moises Chica, MD San Antonio, TX USA(210) 615-1311moises.chica@gmail.comFellowship: Retina and Vitreous of Texas# of prior years at ARDS: 5

16 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Participants | ARDS 2016

Ryan D. Christensen, MD Guest: Erin Shawnee Mission, KS USA(913) 940-0889vitrector1@gmail.comFellowship: Retina Associates, P.A.# of prior years at ARDS: 3

Steven R. Cohen, MD Guest: Rose Sohraby Shawnee Mission, KS USA(314) 324-0751stevenrosscohen@gmail.comFellowship: University of Michigan# of prior years at ARDS: 0

Joseph M. Coney, MD Beachwood, OH USA(617) 645-0652jconey@retina-assoc.comFellowship: Joslin Diabetes Center/Harvard Medical School# of prior years at ARDS: 4

Gwen Cousins, MD New Orleans, LA USA(504) 250-9710gwencousins@yahoo.comFellowship: Gitter and Cohen Retina Associates# of prior years at ARDS: 7

Donald J. D’Amico, MD (Faculty)Guests: Kim Sippel, Arianna New York, NY USA(917) 526-2696djd2003@med.cornell.eduFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 35

Svenja K. Deuchler, MD Frankfurt, Germany+49-17661566368s.deuchler@icloud.com# of prior years at ARDS: 2

David Eichenbaum, MD Guests: Erin, Miriam St. Petersburg, FL USA(727) 744-0856deichenb@yahoo.comFellowship: Tufts/New England Eye Center# of prior years at ARDS: 8

Charles W. Eifrig, MD Newport Beach, CA USA(949) 636-7334ceifrig@yahoo.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 6

Kori Elkins, MD Virginia Beach, VA USA(319) 331-3840kori.elkins@gmail.comFellowship: University of Iowa# of prior years at ARDS: 6

Andrew W. Eller, MD Pittsburgh, PA USA(412) 512-5307elleraw@upmc.eduFellowship: Massachusetts Eye and Ear Infirmary# of prior years at ARDS: 10

Enrique Eng, MD Mexico City, Mexico+52(55)239147retinaeng@yahoo.com.mx# of prior years at ARDS: 3

Robert Feig, MDBrooklyn, NY USA(718) 312-2138feigmd@gmail.comFellowship: UT Southwestern# of prior years at ARDS: 2

Philip J. Ferrone, MD Guest: Jeanine Great Neck, NY USA(516) 220-1594 • pjferrone@gmail.comFellowship: Associated Retinal Consultants/William Beaumont Hospital# of prior years at ARDS: 5

Harry W. Flynn, Jr., MD (Faculty)Guest: Donna Miami, FL USA(305) 333-5982hflynn@med.miami.eduFellowship: California Pacific Medical Center# of prior years at ARDS: 30

ARDS 2016 • SNOWMASS, COLORADO 17

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Robert E. Foster, MD Cincinnati, OH USA(513) 706-6163rfoster@cincinnatieye.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 8

Steve Friedlander, MD Guest: Monica House Reno, NV USA(775) 848-1014steve@pyramid.netFellowship: University of Illinois# of prior years at ARDS: 2

John Frisbee, MD Metairie, LA USA(217) 801-3041frisbee44@msn.comFellowship: Ochsner Medical Center# of prior years at ARDS: 3

Brett Gerwin, MD Chattanooga, TN USA(205) 335-4491bdgerwin@yahoo.comFellowship: UAB/Callahan Eye Foundation# of prior years at ARDS: 0

Christine R. Gonzales, MD Guest: Mike Read Ashland, OR USA(310) 367-4377creadgonzales@gmail.comFellowship: Jules Stein Eye Institute# of prior years at ARDS: 13

Victor Gonzalez, MDMcAllen, TX USA(956) 778-8875Fellowship: Massachusetts Eye and Ear Infirmary# of prior years at ARDS: 15+

Joseph M. Googe, MD Guests: Patti, Elizabeth, Harris, Matt, Oliver Knoxville, TN USA(865) 567-9645jmgooge@aol.comFellowship: Retina Associates of Boston# of prior years at ARDS: 10

Amanda H. Greaves, MBBS Hons FRANZCO FRACSBrisbane, Australia+61-4177485891ahgreaves@gmail.com# of prior years at ARDS: 0

Jeffrey Gross, MD Guest: Kay Columbia, SC USA(803) 736-7200jggross.crc@gmail.comFellowship: University of California, San Diego# of prior years at ARDS: 26

Mrinali Gupta, MD Guest: Arun New York, NY USA(919) 608-9699mrinali@gmail.comFellowship: Weill Cornell Medical College# of prior years at ARDS: 0

David R. Guyer, MD New York, NY USA(917) 747-6389mala.hintzen@ophthotech.comFellowship: Massachusetts Eye and Ear Infirmary# of prior years at ARDS: 15

Curtis L. Hagedorn, MD Denver, CO USA(303) 877-3024chagedorn@retinacolorado.comFellowship: Yale University# of prior years at ARDS: 5

Robert Hampton, MDSyracuse, NY USA(315) 445-8166bhampton@twcny.rr.comFellowship: Albany Medical College / Moorfields# of years at ARDS: 33

Dennis P. Han, MD Milwaukee, WI USA(414) 530-4013dhan@mcw.eduFellowship: Medical College of Wisconsin# of prior years at ARDS: 28

18 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Timothy B. Hanley, MD Guest: Sally, Kathy Bendix Traverse City, MI USA(231) 218-3339h-md@sbcglobal.netFellowship: Albany Medical College# of prior years at ARDS: 30

Mark Harooni, MDBrooklyn, NY USA(718) 312-2138markharooni@gmail.comFellowship: Charles Schepens# of prior years at ARDS: 0

April E. Harris, MDOro Valley, AZ USA(520) 603-8498aeharris31@hotmail.comFellowship: UT Southwestern# of prior years at ARDS: 5

Tarek S. Hassan, MD (Faculty)Royal Oak, MI USA(734) 476-4220tsahassan@yahoo.comFellowship: Associated Retina Consultants/William Beaumont Hospital# of prior years at ARDS: 12

Steven Houston, MD Lake Mary, FL USA(407) 404-1597shouston3@gmail.comFellowship: Wills Eye Hospital# of prior years at ARDS: 0

Mark S. Humayun, MD, PhD Los Angeles, CA USA(818) 415-1732humayun@usc.eduFellowship: Wilmer Eye Institute# of prior years at ARDS: 15

Robert K. Hutchins, MD Cincinnati, OH USA(513) 470-9989rkhutchins@earthlink.netFellowship: Massachusetts Eye and Ear Infirmary# of prior years at ARDS: 10+

Glenn J. Jaffe, MD (Faculty)Durham, NC USA(919) 451-9963jaffe001@mc.duke.eduFellowship: Medical College of Wisconsin# of prior years at ARDS: 5+

Glen Jarus, MD Whittier, CA USA(562) 201-7102gjarus@yahoo.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 3

Mark W. Johnson, MD (Faculty)Guest: Linda Ann Arbor, MI USA(734) 474-7312markwj@umich.eduFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 15

John Kennedy, MB, BS, FRANZCO Guest: Roslyn Darling Point, Australia+61-418245568jkennedy@bigpond.net.au# of prior years at ARDS: 0

Lydell C. Kiplin, MD Guests: Linda and Donald Griffith San Antonio, TX USA(210) 240-9438lckiplin@sbcglobal.net# of prior years at ARDS: 41

Szilard Kiss, MD (Faculty)Guest: Zsofia Stadler New York, NY USA(617) 304-1691szk7001@med.cornell.eduFellowship: Massachusetts Eye and Ear Infirmary# of prior years at ARDS: 10

Frank HJ Koch, MD Frankfurt, Germany+49-17-2-2522389fkoch1@mac.com# of prior years at ARDS: 5

ARDS 2016 • SNOWMASS, COLORADO 19

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Mark Kwong, MD Phoenix, AZ USA(602) 989-3048seemd@hotmail.comFellowship: Associated Retina Consultants/William Beaumont Hospital# of prior years at ARDS: 0

John S. Lean, MD San Juan Capistrano, CA USA(949) 338-7718jlean@cox.netFellowship: Moorfields Eye Hospital# of prior years at ARDS: 35

Craig Leong, MDWalnut Creek, CA USA(925) 876-2323Fellowship: Cornell University Medical College# of prior years at ARDS: 30

Alan Luckie, FRANZCO Albury, Australia+61-2-60213755alanluckie@me.comFellowship: Moorfields, California Pacific, RVEEH# of prior years at ARDS: 7

Susan M. Malinowski, MD Guest: Gary Shapiro Southfield, MI USA(248) 752-4615smmalinowski@aol.comFellowship: Medical College of Wisconsin# of prior years at ARDS: 20

Bob Mames, MD Guest: Ann Huynh Gainesville, FL USA(352) 333-5050mnr352352@yahoo.comFellowship: Tufts/New England Eye Center# of prior years at ARDS: 20+

Jim Martin, BSC, MD, FRCS Guest: Janice Pinto Hamilton, ON Canada(905) 570-3002jmartin23@cogeco.caFellowship: Mayo Clinic# of prior years at ARDS: 4

Archie J. McGeorge, MBChB, PhD Guest: Kathryn Philipson Auckland, New Zealand+64-21738462mcgeorge@win.co.nzFellowship: University of Iowa# of prior years at ARDS: 10+

Desmond E. McGuire, MD Santa Ana, CA USA(949) 500-3074desimcguire@yahoo.comFellowship: UCSD/Shiley Eye Center# of prior years at ARDS: 5

Nick J. McLane, MD Guests: Jann, Christina and Dustin Arendt Greenville, SC USA(864) 270-1737mclane56@aol.comFellowship: LSU Eye Center# of prior years at ARDS: 31

Walter C. McLean, MD Asheville, NC USA(828) 231-1331wcra1@aol.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 30

Calvin E. Mein, MD San Antonio, TX USA(210) 347-1910cemein@gmail.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 31

Toufic S. Melki, MD Rockville, MD USA(703) 395-8683retinacenter01@gmail.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 20

Rohan Merani, MBBS, MMed, FRANZCOFive Dock, Australia+61-4-03179394rohanmerani@gmail.comFellowship: Medical Retina Fellowship, Westmead Hospital, Sydney, NSW, Australia# of prior years at ARDS: 1

20 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Robert Millay, MD Guest: Donna Shelburne, VT USA(802) 985-4107robert.millay@uvmhealth.orgFellowship: Oregon Health and Science University# of prior years at ARDS: 10

John B. Miller, MD Guest: Karen Kinnaman Boston, MA USA(617) 549-2081john_miller@meei.harvard.eduFellowship: Massachusetts Eye and Ear Infirmary# of prior years at ARDS: 0

Jeffrey K. Moore, MD Portland, ME USA(207) 774-8277jmoore.mec@gmail.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 10+

Alexander Movshovich, MD Guest: Polina Ilnitskaya Cliffside Park, NJ USA(917) 880-1479amovshovich@gmail.comFellowship: Cornell University Medical College# of prior years at ARDS: 6

Richard S. Munsen, MD Guest: Deidra Wager Seattle, WA USA(206) 898-0290rmunsen@msn.comFellowship: University of Iowa# of prior years at ARDS: 34

Timothy G. Murray, MD, MBA (Faculty)Guests: Nicole, Jules, Ali Miami, FL USA(786) 368-9638tmurray@murraymd.comFellowship: Medical College of Wisconsin# of prior years at ARDS: 15+

Phil Nelsen, MD Toledo, OH USA(419) 297-7753aniter4@aol.comFellowship: Albany Medical College# of prior years at ARDS: 20

Brent C. Norman, MD Guest: Denise Newport Beach, CA USA(949) 246-5926bcnorman@cox.netFellowship: USC - Doheny Eye Institute# of prior years at ARDS: 25

John C. Olson, MD Guest: Kathryn Orlando, FL USA(321) 331-1851jcolson.mco@gmail.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 25+

Anton Orlin, MD Guest: Emily Tabas New York, NY USA(610) 246-2859aorlin@gmail.comFellowship: Weill Cornell Medical College# of prior years at ARDS: 5

Mike O’Rourke, BSc. MBChB, FRANZCO Guest: Chantal Tauranga, New Zealand+64-21829355mikeor4@gmail.com# of prior years at ARDS: 5

David W. Parke, II, MD (Faculty)Guest: Julie San Francisco, CA USA(405) 202-0920dparke@aao.orgFellowship: Baylor College of Medicine# of prior years at ARDS: 30

D. Wilkin Parke, III, MD Guest: Marion Minneapolis, MN USA(405) 431-9362wilkinparke@gmail.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 4

David J. Parks, MD Beverly Hills, CA USA(310) 289-3666Fellowship: White Memorial Medical Center# of prior years at ARDS: 13

ARDS 2016 • SNOWMASS, COLORADO 21

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Raul Perez, MD San Juan, PR USA(787) 455-4907perez@btinet.netFellowship: UPR School of Medicine# of prior years at ARDS: 10

Matthew Pezda, MD Las Vegas, NV USA(305) 987-7226matthew.pezda@gmail.comFellowship: University of Toronto# of prior years at ARDS: 4

Irene M. Rusu, MD Guest: Avi Jutagir New York, NY USA(508) 254-4936irenerusu@gmail.comFellowship: Cornell University Medical College# of prior years at ARDS: 0

Edwin H. Ryan, MD Guest: Jenni Edina, MN USA(612) 735-0669edryan1@mac.comFellowship: Washington University, St. Louis# of prior years at ARDS: 10

Dianne Sharp, FRANZCO Auckland, New Zealand+64-274820715dianne@retinaspecialists.co.nzFellowship: Moorfields Eye Hospital# of prior years at ARDS: 0

Jonathan Sheindlin, MDBrooklyn, NY USA(718) 312-2138jsheindlin@gmail.comFellowship: Charles Schepens# of prior years at ARDS: 0

Yossi Sidikaro, MD, PhD Beverly Hills, CA USA(310) 497 3030ysretina@aol.comFellowship: Bascom Palmer Eye Institute/Wilmer Eye Institute# of prior years at ARDS: 30

Christopher N. Singh, MD Grand Blanc, MI USA(206) 384-3093singhcn@gmail.comFellowship: Kresge Eye Institute# of prior years at ARDS: 7

Pankaj Singh, MD Frankfurt, Germany+49-1797062477singhpankaj@me.comFellowship: # of prior years at ARDS: 2

Alexandrea C. Souto, MD Campinas, Brazil+55-54-1932130100retinaldc@terra.com.brFellowship: Jules Stein Eye Institute# of prior years at ARDS: 0

Giovanni Staurenghi, MD (Faculty)Milano, Italy+39-3355276270giovanni.staurenghi@unimi.it# of prior years at ARDS: 3

Charles Stewart, MD Johannesburg, South Africa+27- 825780686cstewart@iafrica.com# of prior years at ARDS: 1

Ivan J. Suner, MD, MBA Guest: Elise Miller Tampa, FL USA(813) 205-6611ivansuner@gmail.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 12

Homayoun Tabandeh, MD Beverly Hills, CA USA(310) 614-5412tabandeh100@gmail.comFellowship: Bascom Palmer Eye Institute & Moorfields Eye Hospital# of prior years at ARDS: 0

22 ASPEN RETINAL DETACHMENT SOCIETY MEETING

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

Martin L. Thomley, MD Birmingham, AL USA(205) 937-4474mthomley@gmail.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 15

Thierry S. Verstraeten, MD Pittsburgh, PA USA(412) 576-6560verstraeten3@comcast.netFellowship: Associated Retinal Consultants/William Beaumont Hospital# of prior years at ARDS: 20+

Brian Ward, MD, PhD Campbell, CA USA(408) 679-0132bwardrdc@yahoo.comFellowship: UCLA/Jules Stein Eye Institute# of prior years at ARDS: 30+

John C. Welch, MD Hastings, NE USA(402) 461-8102jaydub@tcgcs.comFellowship: Wills Eye Hospital# of prior years at ARDS: 27

Robert Welch, FNP Guest: Carissa Reno, NV USA(775) 356-7272robnevada@yahoo.com# of prior years at ARDS: 0

Basil K. Williams, MD Miami, FL USA(917) 692-6789basilkwilliams@gmail.comFellowship: Bascom Palmer Eye Institute# of prior years at ARDS: 0

David F. Williams, MD Minneapolis, MN USA(952) 931-0451dfws2@mac.comFellowship: Medical College of Wisconsin # of prior years at ARDS: 25

Jeremy D. Wolfe, MD Royal Oak, MI USA(248) 320-7401jwolfe@arcpc.netFellowship: Wills Eye Hospital# of prior years at ARDS: 5

Keye L. Wong, MD Guests: Lucy, Lindsay Sarasota, FL USA(941) 374-4491keyewong.ras@gmail.comFellowship: Pacific Presbyterian Medical Center# of prior years at ARDS: 10+

Mia Woodward, MD Ann Arbor, MI USA(248) 320-7401miawoodward@gmail.comFellowship: Emory University# of prior years at ARDS: 5

Martin A. Worrall, MD Tucson, AZ USA(520) 909-1563worrallm@juno.comFellowship: Baylor College of Medicine# of prior years at ARDS: 5

David Worsley, MBChB Hamilton, New Zealand+64-7-8340006aworsley@xtra.co.nzFellowship: Bristol Eye Hospital# of prior years at ARDS: 20

George J. Wyhinny, MD Des Plaines, IL USA(847) 712-3933mwretina@sbcglobal.netFellowship: University of Illinois# of prior years at ARDS: 20

Nicholas Zakov, MD Chagrin Falls, OH USA(216) 235-2070normal@retina-assoc.comFellowship: Bascom Palmer Eye Institute & Massachusetts Eye and Ear Infirmary# of prior years at ARDS: 30

ARDS 2016 • SNOWMASS, COLORADO 23

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .

EXHIBITORSThe Aspen Retinal Detachment Society gratefully acknowledges

generous contributions from these companies:

NBLACK DIAMONDN

Genentech, Inc.

NDIAMONDN

Insight Instruments, Inc.Regeneron Pharmaceuticals, Inc.

NPLATINUMN

Alimera SciencesBausch + Lomb

NGOLDN

Alcon Laboratories, Inc.Allergan, Inc.

Dutch Ophthalmic, USAMedOne Surgical, Inc.OCULUS Surgical, Inc.

Optos, Inc.ThromboGenics, Inc.

NSILVERN

Notal VisionSanten, Inc.

MEDICAL CONFERENCE PLANNERS, INC.

914-722-0664

ards@medconfs.com • www.medconfs.com • www.aspenretina.com